Published in BMC Infect Dis on January 12, 2010
Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV. J R Soc Interface (2012) 1.05
A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med (2014) 1.01
Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models. Adv Drug Deliv Rev (2013) 0.89
Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus. Vaccines (Basel) (2014) 0.75
Human immunodeficiency virus/acquired immune deficiency syndrome: Using drug from mathematical perceptive. World J Virol (2015) 0.75
An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART). AIDS Behav (2017) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med (1999) 7.28
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis (2008) 4.86
The dynamics of CD4+ T-cell depletion in HIV disease. Nature (2001) 4.37
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr (2005) 3.33
Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics (2006) 2.95
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Adherence to HIV combination therapy. Soc Sci Med (2000) 2.39
Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2005) 2.32
Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS (2008) 2.05
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet (1998) 1.88
Attaining higher goals in HIV treatment: the central importance of adherence. AIDS (1999) 1.88
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med (1998) 1.88
The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS (1999) 1.78
The era of adherence to HIV therapy. Ann Intern Med (1998) 1.55
Can the viral reservoir of latently infected CD4(+) T cells be eradicated with antiretroviral HIV drugs? J Math Biol (2009) 1.47
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med (2004) 1.41
Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials (2007) 1.38
Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci (2003) 1.35
Adherence and drug resistance: predictions for therapy outcome. Proc Biol Sci (2000) 1.34
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med (2007) 1.17
Optimal drug treatment regimens for HIV depend on adherence. J Theor Biol (2007) 1.08
Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother (2000) 1.07
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS (2002) 1.05
Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bull Math Biol (2004) 1.04
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database Syst Rev (2006) 1.00
Abacavir: a review of its clinical potential in patients with HIV infection. Drugs (2000) 1.00
Delavirdine: a review of its use in HIV infection. Drugs (2000) 0.99
Protease inhibitor-sparing regimens: new evidence strengthens position. J Acquir Immune Defic Syndr (2003) 0.98
The AIDS epidemic--a progress report from Mexico City. N Engl J Med (2008) 0.98
Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS (2001) 0.97
Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? Proc Biol Sci (2006) 0.97
Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J R Soc Interface (2005) 0.96
Public health consequences of screening patients for adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 0.90
Didanosine: an updated review of its use in HIV infection. Drugs (1999) 0.84
Emtricitabine: a review of its use in the management of HIV infection. Drugs (2005) 0.82
Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be? Math Biosci (2008) 0.79
Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput Biol (2007) 0.79
Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection. Paediatr Drugs (2002) 0.77
IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med (2003) 3.29
Early optical polarization of a gamma-ray burst afterglow. Science (2007) 2.37
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab (2011) 1.63
Hyperglycemia enhances the cytokine production and oxidative responses to a low but not high dose of endotoxin in rats. Crit Care Med (2005) 1.55
Inhibition of interleukin-6-activated janus kinases/signal transducers and activators of transcription but not mitogen-activated protein kinase signaling in liver of endotoxin-treated rats. Crit Care Med (2002) 1.45
CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol (2012) 1.40
Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. N Engl J Med (2015) 1.34
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care (2011) 1.31
Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone (2003) 1.29
The failure of R0. Comput Math Methods Med (2011) 1.26
Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet (2008) 1.23
The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signaling. Endocrinology (2005) 1.22
Mechanical regulation of mitogen-activated protein kinase signaling in articular cartilage. J Biol Chem (2003) 1.19
The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. N Engl J Med (2013) 1.16
The impact of media coverage on the transmission dynamics of human influenza. BMC Public Health (2011) 1.15
Creating larger and better connected protected areas enhances the persistence of big game species in the maputaland-pondoland-albany biodiversity hotspot. PLoS One (2013) 1.10
Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. J Biol Chem (2003) 1.09
A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development. Mol Cell Biol (2012) 1.09
Personalized medicine in diabetes. Clin Chem (2010) 1.04
Halting HIV/AIDS with avatars and havatars: a virtual world approach to modelling epidemics. BMC Public Health (2009) 0.97
Conservation planning when costs are uncertain. Conserv Biol (2010) 0.96
Cheap and nasty? The potential perils of using management costs to identify global conservation priorities. PLoS One (2013) 0.96
Hyperglycemia induced by glucose infusion causes hepatic oxidative stress and systemic inflammation, but not STAT3 or MAP kinase activation in liver in rats. Metabolism (2003) 0.94
Effects of protein malnutrition on IL-6-mediated signaling in the liver and the systemic acute-phase response in rats. Am J Physiol Regul Integr Comp Physiol (2004) 0.94
Distinct Grb10 domain requirements for effects on glucose uptake and insulin signaling. Mol Cell Endocrinol (2005) 0.93
Modelling the dynamics of crystal meth ('tik') abuse in the presence of drug-supply chains in South Africa. Bull Math Biol (2012) 0.93
Evaluating biodiversity conservation around a large Sumatran protected area. Conserv Biol (2008) 0.86
The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk. Metab Syndr Relat Disord (2011) 0.86
GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling. Hum Mol Genet (2009) 0.85
Alcohol use of diabetes patients: the need for assessment and intervention. Acta Diabetol (2010) 0.84
Using a systematic approach to select flagship species for bird conservation. Conserv Biol (2013) 0.83
A mathematical model of avian influenza with half-saturated incidence. Theory Biosci (2013) 0.82
Predicting the HIV/AIDS epidemic and measuring the effect of mobility in mainland China. J Theor Biol (2012) 0.82
Acute effects of hyperglycemia and hyperinsulinemia on hepatic oxidative stress and the systemic inflammatory response in rats. Crit Care Med (2007) 0.82
Antiviral activity of hop constituents against a series of DNA and RNA viruses. Antiviral Res (2004) 0.82
Non-smooth plant disease models with economic thresholds. Math Biosci (2012) 0.81
Assessing the clinical benefits of lipid-disorder drugs. N Engl J Med (2014) 0.81
Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide. J Theor Biol (2010) 0.80
Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination? BMC Public Health (2008) 0.79
From regional pulse vaccination to global disease eradication: insights from a mathematical model of poliomyelitis. J Math Biol (2014) 0.79
Brief Alcohol Intervention Among At-Risk Drinkers with Diabetes. Subst Abuse (2010) 0.78
Response to Foss et al., 'Care should be taken when promoting microbicide use among sex workers who are able to use condoms consistently'. AIDS (2005) 0.76
Revisiting the links between governance and biodiversity loss. Conserv Biol (2007) 0.75
Baker et al overlook Memphis' Dr Myles V. Lynk, NMA pioneer. J Natl Med Assoc (2009) 0.75
Endotoxin-Induced Inhibition of Growth Hormone Receptor Signaling in Rat Liver in Vivo1. Endocrinology (1999) 0.75
Resistance to protease inhibitors in a model of HIV-1 infection with impulsive drug effects. Bull Math Biol (2013) 0.75